Incyte Corp. has created two new units in anticipation of future growth in the U.S. and internationally. A new U.S. country organization will lead commercial and medical affairs in the U.S., and a Global Product Strategy and Business Development & Licensing (BD&L) unit will lead global competitive strategies for Incyte’s portfolio beyond Jakafi (ruxolitinib).   Jim Daly will leave Incyte later this month, and commented, “My decision to return to California was a personal one. I leave Inc...